Subsequent experiments comparing the proliferation of cancer cells bearing wild-type HRAS and oncogenic HRAS mutations revealed an intrinsic vulnerability of oncogenic HRAS-driven cancer cells to genetic depletion or pharmacological inhibition of TRPML1. This evidence concerns the gene HRAS and cancer.